Annovis Bio (ANVS)

$10.96

+0.49

(+4.68%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $10.20
    $11.19
    $10.96
    downward going graph

    6.96%

    Downside

    Day's Volatility :8.87%

    Upside

    2.06%

    downward going graph
  • $4.79
    $22.49
    $10.96
    downward going graph

    56.3%

    Downside

    52 Weeks Volatility :78.7%

    Upside

    51.27%

    downward going graph

Returns

PeriodAnnovis BioSector (Health Care)Index (Russel 2000)
3 Months
-41.87%
6.5%
0.0%
6 Months
5.65%
7.1%
0.0%
1 Year
-20.62%
9.8%
0.0%
3 Years
-90.86%
14.2%
-20.2%

Highlights

Market Capitalization
120.3M
Book Value
- $0.3
Earnings Per Share (EPS)
-5.14
Wall Street Target Price
35.25
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-160.65%
Return On Equity TTM
-566.49%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
Diluted Eps TTM
-5.14
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.31
EPS Estimate Next Year
-2.07
EPS Estimate Current Quarter
-0.8
EPS Estimate Next Quarter
-0.47

Analyst Recommendation

Buy
    72%Buy
    27%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Annovis Bio(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
9
10
Hold
3
2
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 221.62%

Current $10.96
Target $35.25

Technicals Summary

Sell

Neutral

Buy

Annovis Bio is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Annovis Bio
Annovis Bio
82.72%
5.65%
-20.62%
-90.86%
9.18%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Annovis Bio
Annovis Bio
NA
NA
NA
-1.31
-5.66
-1.61
NA
-0.3
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Annovis Bio
Annovis Bio
Buy
$120.3M
9.18%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on Annovis Bio

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 82.2%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 277.4%

Institutional Holdings

  • Vanguard Group Inc

    3.20%

  • Adage Capital Partners Gp LLC

    2.24%

  • BlackRock Inc

    0.87%

  • Susquehanna International Group, LLP

    0.65%

  • Geode Capital Management, LLC

    0.63%

  • Wescott Financial Advisory Group, LLC

    0.37%

Company Information

annovis bio, inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. its lead compound is anvs401, which is in phase 2a clinical trials for the treatment of alzheimer's disease (ad), parkinson's disease, alzheimer's disease in down syndrome, and other chronic neurodegenerative disorders. the company is also developing anvs405 for protecting the brain after traumatic brain injury and/or stroke; and anvs301, which is in phase i clinical trials to increase cognitive capability in later stages of ad and dementia. annovis bio, inc. was founded in 2008 and is based in berwyn, pennsylvania.

Organization
Annovis Bio
Employees
6
CEO
Dr. Maria L. Maccecchini Ph.D.
Industry
Electronic Equipment/Instruments

Discover More

FAQs